ClinicalTrials.gg
RecruitingNCT07673640Updated Sep 8, 2026

Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study

An observational study in Non-Segmental Vitiligo (NSV), sponsored by ShanShan Li. Recruiting at 20 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by ShanShan Li · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies in Vitiligo with a site in China — 24 open to participants now, 29 under way, 8 of them phase 3. Vitiligo · China.

Started
2026
with 11 others
Observational
7 of 39
3 open now
Primary completion
2026-12
later than 7 of 28 live
Registered
34th of 39
by date

Among the 39 studies in Vitiligo with a site in China, this one is one of 12 that started in 2026, is one of 7 observational ones, reaches primary completion later than 7 of the 28 other live ones, and was the 34th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 95 are open to participants now.

Browse Vitiligo studies →

Open to participants now

24 of the 39 studies in Vitiligo with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Vitiligo studies recruiting now, 13 (28%) set no upper age limit and 28 (60%) stop at 75 or younger; 17 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Vitiligo with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world clinical setting. The study plans to observe patients aged 12 years and older with active, progressive non-segmental vitiligo involving the face. All treatments are prescribed based on standard routine clinical care and medical practice guidelines. Participants will apply Ruxolitinib cream twice daily to affected skin areas for up to 24 weeks alongside a standard corticosteroid regimen. The primary goal of the study is to evaluate how many patients achieve a 75% or greater improvement in their facial vitiligo patches after 12 weeks of combined treatment. Safety and side effects will also be closely monitored throughout the 24-week period.

Read the detailed description

This prospective, multicenter, real-world cohort study plans to enroll 300 patients with active, progressive non-segmental vitiligo. Following routine medical diagnosis and standard-of-care clinical decisions, patients will receive treatment combining topical 1.5% Ruxolitinib phosphate cream applied twice daily (maximum 2 tubes/200g per month) for up to 24 weeks with concurrent corticosteroid therapy. Corticosteroid regimens consist of either intramuscular Compound Betamethasone injection (1ml once monthly) or Dexamethasone oral low-dose pulse therapy (2.25mg single dose once daily on Saturdays and Sundays) for a maximum duration of 24 weeks.The sample size of 300 patients is mathematically powered to test a superiority hypothesis. While historical single-center real-world data for ruxolitinib cream monotherapy demonstrated a 12-week response rate of 24.7%, this study establishes a conservative historical target control threshold baseline (P0) of 24%. Assuming the real-world addition of corticosteroid pulse therapy achieves an improved true response rate (P1) of 32%, a sample size of 237 evaluable participants provides 80% statistical power (beta = 0.20) to reject the null hypothesis using a two-sided exact binomial test at a significance level of alpha = 0.05. Accounting for an expected 20% drop-out or loss-to-follow-up rate, the final enrollment target was set to 300 participants. Efficacy analyses for the primary endpoint at Week 12 will utilize Multiple Imputation methods to account for missing data under Missing at Random (MAR) assumptions.

03

Conditions studied

  • Non-Segmental Vitiligo (NSV)

Browse trials for

Keywords

  • Ruxolitinib phosphate cream
  • Corticosteroid therapy
  • Multicenter study
  • Real-world study
  • Active Vitiligo
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Males and females aged 12 and older presenting with active, progressive non-segmental vitiligo with facial involvement and a total body surface area (BSA) depigmentation under 10%. Subjects are selected via a non-probability clinical recruitment strategy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 12 years at the time of signing .
  • Clinical diagnosis of non-segmental vitiligo with facial involvement, and total body surface area (BSA) depigmentation ≤ 10%.
  • Diagnosed with progressive/active vitiligo meeting at least one of the following: Vitiligo Disease Activity (VIDA) score ≥ 3.

Clinical signs including trichrome vitiligo, confetti-like depigmentation, or Koebner phenomenon.

The extent of lesions under Wood's lamp is larger than that visible to the naked eye.

  • Agrees to have no pregnancy plans and uses effective during the study and up to 4 weeks after the last dose.
  • Voluntarily signs the informed consent form and agrees to regular follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of other clinical forms of vitiligo (e.g., segmental vitiligo).
  • Clinically diagnosed with stable vitiligo.
  • Co-existing skin depigmentation disorders affecting efficacy evaluation (e.g., pityriasis alba, leprosy, post-inflammatory hypopigmentation, progressive macular hypomelanosis, nevus anemicus, chemical leukoderma, tinea versicolor).
  • Leukoderma lesions with more than 1/3 white hair, or lesions accompanied by white hair where the investigator assesses the probability of benefit from participating is low based on clinical experience.
  • to systemic use.
  • Known or allergy to the study medications or .
  • Known end-stage renal disease (ESRD) or currently undergoing renal replacement therapy (e.g., dialysis).
  • Concurrent participation in other clinical studies.
  • Any other condition which, in the investigator's judgment, makes the patient unsuitable for the study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Interventions

  • DrugRuxolitinibStudies of RuxolitinibRuxolitinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Applied topically twice daily (BID), maximum 2 tubes per month (100g/tube) for a total duration of 24 weeks

  • DrugCorticosteroid Therapy

    Either Compound Betamethasone injection (1ml, intramuscularly once a month) OR Dexamethasone oral low-dose pulse therapy (2.25mg, single dose once daily on Saturdays and Sundays) . Maximum hormone duration is 24 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Facial Vitiligo Area Scoring Index 75 (F-VASI 75)

    The percentage of patients achieving a ≥ 75% improvement from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) score. F-VASI measures facial depigmentation using the Palmar method (1% Body Surface Area (BSA) corresponds to one hand surface area of the participant) across facial anatomical regions with a total score range of 0 to 3. Higher scores represent greater depigmentation. Missing primary endpoint data will be handled via Multiple Imputation based on Missing at Random (MAR) assumptions.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of Participants Achieving F-VASI 50 and F-VASI 90

    Percentage of participants achieving a ≥50% or ≥90% improvement from baseline in the Facial Vitiligo Area Scoring Index (F-VASI).

    Time frame: Weeks 4, 8, 12, and 24

  2. Proportion of Participants Achieving F-VASI 75 at Remaining Timepoints

    Percentage of participants achieving a ≥75% improvement from baseline in the Facial Vitiligo Area Scoring Index (F-VASI).

    Time frame: Weeks 4, 8, and 24

  3. Proportion of Participants Achieving T-VASI 50, T-VASI 75, and T-VASI 90

    Percentage of participants achieving a ≥50%, ≥75%, or ≥90% improvement from baseline in the Total Vitiligo Area Scoring Index (T-VASI).

    Time frame: Weeks 4, 8, 12, and 24

  4. Change From Baseline in Vitiligo Disease Activity (VIDA) Score

    Evaluation of the mean change in disease progression activity using the VIDA score ranking scale.

    Time frame: Weeks 4, 8, 12, and 24

  5. Change From Baseline in Facial Body Surface Area (F-BSA) and Total Body Surface Area (T-BSA)

    Evaluation of the mean changes in percentage values for facial and total body surface area affected by vitiligo.

    Time frame: Weeks 4, 8, 12, and 24

  6. Change From Baseline in F-VASI and T-VASI Scores

    Continuous absolute scoring changes from baseline evaluation across both indices.

    Time frame: Weeks 4, 8, 12, and 24

  7. Proportion of Participants Achieving a Vitiligo Noticeability Scale (VNS) Score of 4 or 5

    Percentage of participants rating their lesions as 4 ("a lot less noticeable") or 5 ("no longer noticeable") on the patient-reported VNS scale, alongside individual category breakdowns.

    Time frame: Weeks 4, 8, 12, and 24

Other outcomes

  1. Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Drug Reactions (ADRs)

    Assessment of total safety events, with a specific focus on application-site reactions such as acne and pruritus.

    Time frame: Throughout the study period (Up to Week 24)

  2. Proportion of Participants Discontinuing Treatment or Withdrawing Due to Adverse Events

    Evaluation of tolerability based on safety discontinuation metrics.

    Time frame: Throughout the study period (Up to Week 24)

07

Study locations

6 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 25 observational studies under Vitiligo, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 31, 2028
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07673640
Lead sponsor
ShanShan Li
Responsible party
ShanShan Li (PI, Dermavon Holdings Limited) — Sponsor-investigator
First posted
Jun 29, 2026
Start date
Jul 2, 2026
Primary completion
Dec 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 8, 2026

Study contacts

ShanShan Li
Contact
lishanshan@cms.net.cn
+86 18201346463

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion